PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
176.45 - 178.59
86.62 - 184.48
124.91M / 173.95M (Avg.)
50.81 | 3.50
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
13.05%
Revenue growth above 1.5x MRVL's 6.87%. David Dodd would confirm if the firm has a unique advantage driving sales higher.
19.02%
Gross profit growth above 1.5x MRVL's 7.09%. David Dodd would confirm if the company's business model is superior in terms of production costs or pricing.
656.99%
EBIT growth above 1.5x MRVL's 46.35%. David Dodd would confirm if core operations or niche positioning yield superior profitability.
656.99%
Operating income growth above 1.5x MRVL's 46.35%. David Dodd would confirm if consistent cost or pricing advantages drive this outperformance.
405.55%
Net income growth above 1.5x MRVL's 52.30%. David Dodd would check if a unique moat or cost structure secures superior bottom-line gains.
333.33%
EPS growth above 1.5x MRVL's 45.45%. David Dodd would review if superior product economics or effective buybacks drive the outperformance.
333.33%
Diluted EPS growth above 1.5x MRVL's 50.00%. David Dodd would see if there's a robust moat protecting these shareholder gains.
-0.13%
Share reduction while MRVL is at 1.28%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
-2.61%
Reduced diluted shares while MRVL is at 1.56%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.
No Data
No Data available this quarter, please select a different quarter.
101.50%
OCF growth above 1.5x MRVL's 36.49%. David Dodd would confirm a clear edge in underlying cash generation.
70.07%
FCF growth above 1.5x MRVL's 34.40%. David Dodd would verify if the firm’s strategic investments yield superior returns.
276.85%
10Y revenue/share CAGR at 50-75% of MRVL's 415.23%. Martin Whitman would question if the firm’s offerings lag behind the competitor.
276.85%
5Y revenue/share CAGR at 50-75% of MRVL's 415.23%. Martin Whitman would worry about a lagging mid-term growth trajectory.
20.73%
3Y revenue/share CAGR under 50% of MRVL's 267.94%. Michael Burry might see a serious short-term decline in relevance vs. the competitor.
-97.07%
Negative 10Y OCF/share CAGR while MRVL stands at 1007.00%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
-97.07%
Negative 5Y OCF/share CAGR while MRVL is at 1007.00%. Joel Greenblatt would question the firm’s operational model or cost structure.
-98.07%
Negative 3Y OCF/share CAGR while MRVL stands at 11152.72%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
73.09%
Below 50% of MRVL's 1324.45%. Michael Burry would worry about a sizable gap in long-term profitability gains vs. the competitor.
73.09%
Below 50% of MRVL's 1324.45%. Michael Burry would worry about a substantial lag vs. the competitor’s profit ramp-up.
-49.77%
Negative 3Y CAGR while MRVL is 135.12%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
698.62%
10Y equity/share CAGR at 75-90% of MRVL's 912.84%. Bill Ackman would push for either higher ROE or more earnings retention to catch the competitor.
698.62%
5Y equity/share CAGR at 75-90% of MRVL's 912.84%. Bill Ackman might push for an improved ROE or share repurchase strategy to keep up.
57.36%
Positive short-term equity growth while MRVL is negative. John Neff sees a strong advantage in near-term net worth buildup.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
24.76%
AR growth well above MRVL's 18.49%. Michael Burry fears inflated revenue or higher default risk in the near future.
11.45%
Inventory growth well above MRVL's 11.19%. Michael Burry suspects overshooting production or weaker sell-through vs. the competitor.
3.97%
Asset growth at 75-90% of MRVL's 5.03%. Bill Ackman suggests reviewing opportunities to match or surpass the competitor's asset expansion if profitable.
1.34%
Under 50% of MRVL's 2.69%. Michael Burry raises concerns about the firm’s ability to build intrinsic value relative to its rival.
-33.27%
Both reduce debt yoy. Martin Whitman sees a broader sector shift to safer balance sheets or less growth impetus.
2.88%
R&D growth drastically higher vs. MRVL's 3.66%. Michael Burry fears near-term margin erosion unless breakthroughs are imminent.
-1.51%
We cut SG&A while MRVL invests at 4.23%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.